Leaflet HUMIRA 80mg solution for injection in pre-filled syringe
Indicated for: inflammatory bowel disease
Route of administration: injectable
Substance: adalimumab (monoclonal antibody)
ATC: L04AB04 (Antineoplastic and immunomodulating agents | Immunosuppressants | Tumor necrosis factor alpha (tnf-alpha) inhibitors)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Avoid live vaccines during treatment if contraindicated.
This medicine may increase the risk of infections.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Adalimumab is a biologic medication used to treat autoimmune inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. It works by inhibiting tumor necrosis factor-alpha (TNF-α), a protein involved in inflammation.
It is administered as subcutaneous injections, usually once every two weeks, depending on the medical indication. Adalimumab helps reduce inflammation, alleviate symptoms, and prevent joint damage.
Side effects may include injection site reactions, respiratory infections, headaches, or nausea. In rare cases, it may increase the risk of severe infections or certain types of cancer.
Patients should be regularly monitored by their doctor and report any signs of infection or other health issues. It is contraindicated in cases of active severe infections.
General data about HUMIRA 80mg
- Substance: adalimumab
- Date of last drug list: 01-06-2017
- Commercial code: W63445001
- Concentration: 80mg
- Pharmaceutical form: solution for injection in pre-filled syringe
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for adalimumab
Concentrations available for adalimumab
- 20mg
- 20mg/0.2ml
- 20mg/0.4ml
- 40mg
- 40mg/0.4ml
- 40mg/0.8ml
- 80mg
- 80mg/0.8ml